Uncovering the genetic underpinnings for different psychiatric disorder combinations

Liangying Yin[1], Menghui Liu[2], Yujia Shi[1], Ruoyu Zhang[1], Simon Sai-Yu Lui[3], Hon-Cheong So[1,4-9*]

[1]School of Biomedical Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong
[2]Department of Epidemiology, College of Public Health and Health Professions, University of Florida, USA
[3]Department of Psychiatry, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China
[4]KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China
[5]Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong
[6]CUHK Shenzhen Research Institute, Shenzhen, China
[7]Margaret K.L. Cheung Research Centre for Management of Parkinsonism, The Chinese University of Hong Kong, Shatin, Hong Kong
[8]Brain and Mind Institute, The Chinese University of Hong Kong, Hong Kong SAR, China
[9]Hong Kong Branch of the Chinese Academy of Sciences Center for Excellence in Animal Evolution and Genetics, The Chinese University of Hong Kong, Hong Kong SAR, China

Correspondence to: Hon-Cheong So, Lo Kwee Seong Integrated Biomedical Sciences Building, The Chinese University of Hong Kong, Shatin, Hong Kong. Tel: +852 3943 9255; E-mail: hcso@cuhk.edu.hk

Abstract

Psychiatric disorders are highly heterogeneous, and it is clinically meaningful to distinguish psychiatric disorders by the presence or absence of a specific comorbid condition. In this study, we employed a recently developed algorithm (CombGWAS) to decipher the genetic basis of psychiatric disorder combinations. The focus was on comorbidities and combinations of disorders, such as major depressive disorder(MDD) with and without schizophrenia(SCZ), which can be considered as two 'subtypes' of MDD. We also studied psychiatric disorders comorbid with obesity as disease subtypes.

Our study identified genetic variants associated with different "subtypes" and the genetic architecture underlying the 16 psychiatric disorder combinations. We also performed further analysis including gene-based (MAGMA), tissue specificity, and pathway enrichment analyses. Genetic correlation and Mendelian randomization(MR) analysis were also performed across different psychiatric disorder "subtypes", and with various cardiovascular diseases(CVD).

We identified 653 risk loci associated with the 16 psychiatric disorder entities. While high genetic correlations(rg) were observed between many subtypes, MDD with and without obesity only showed modest genetic correlation(rg=0.166). Interestingly, most subtype pairs exhibited distinct genetic correlations with the same cardiovascular disease. Some pairs even displayed opposite genetic correlations. For instance, the genetic correlation(rg) between SCZ with obesity and type 2 diabetes(T2DM) was 0.248(p=4.42E-28), while rg between SCZ without obesity and T2DM was -0.154(p=6.79E-12). Using MR, we observed that many psychiatric comorbidities may be causally linked to increased CVD risks, but the effect size differed substantially. Comorbid psychiatric disorders typically display different causal effects with CVD compared to single psychiatric disorders without comorbidities. This study represents a significant step toward unravelling the heterogeneity underlying psychiatric disease combinations and comorbidities, shedding light on their underlying pathophysiology.

Introduction

Psychiatric disorders constitute significant health and societal burdens on a global scale, consistently ranking among the most debilitating medical conditions across diverse age groups[1]. The psychiatric classification systems define diagnostic entities based on phenomenology; and psychiatric co-morbidities are common. For example, a considerable proportion of schizophrenia patients have comorbid depression, obsessive compulsive disorder (OCD) and other psychiatric disorders[2]. Moreover, around 75% of patients with depression have comorbid anxiety disorders. Psychiatric co-morbidity results in 'subtypes' of primary psychiatric disorders, and highlights the vast phenotypic heterogeneity in psychiatry. Importantly, subtypes of a primary disorder with different psychiatric co-morbidity may have distinct neurobiological abnormalities. Clarifying the genetic basis for these different phenotypes with different psychiatric co-morbidity can potentially unveil biological mechanisms and may promote individualized care.

Genome-wide association studies (GWAS) showed promise to reveal the genetic basis of complex disorders[3,4], such as psychiatric disorders. To date, a substantial number of GWAS have explored the genetic architecture of psychiatric disorders, a rapidly advancing research area in psychiatry, boosted by the availability of large-scale biobanks. However, prior research on GWAS mainly focused on exploring the genetic basis of a single psychiatric entity, and largely ignored psychiatric comorbidities.

Our team has recently developed a novel statistical framework, i.e., the CombGWAS[5] to uncover the genetic architecture of different "combinations" of cardiovascular diseases (CVD). This

framework showed promise to identify susceptibility loci and genes associated with specific combinations of CVD, using only the summary statistics of the individual diseases. The validity of the framework has also been verified by extensive simulations and applications to real data [5]. In this study, we attempted to apply the CombGWAS[5] framework to psychiatric co-morbidities. As such, we aimed to identify the genetic signatures that distinguish the two possible 'subtypes' of a psychiatric condition, characterized by the presence or absence of a specific psychiatric and/or metabolic comorbidity. Specifically, we aimed to clarify the shared and distinct genetic basis for 8 pairs of psychiatric subtypes.

We briefly highlight the difference of our approach with other related methods here. Besides CombGWAS[5], the genetic correlation between two psychiatric conditions can be explored by (1) LD score regression (LDSR)[6] , or (2) polygenic risk scores (PRS)[7] analysis. Notably, the LDSR method and PRS association analyses are only able to discover the *overall* genetic correlation or overlap between two psychiatric disorders, and *cannot identify specific susceptibility variants* responsible for the presence/absence of a particular psychiatric comorbidity. Another intuitive approach is to find genetic variants that surpass a significance threshold (e.g. $p<5e-8$) for each trait, and directly find the overlapping variants. However, this method employs an arbitrary significance threshold. If the threshold is too stringent threshold (such as the conventional genome-wide significance cut-off), it will have low power and high risk of missing the genuine genetic variants contributing to the comorbidity. Conversely, if the threshold is too relaxed (e.g. $p<0.05$), it will result in high false positive rates. GWAS meta-analysis [8] is a related topic worth mentioning. In meta-analysis of genetic studies, we aggregate evidence from different studies of the same or highly related traits to improve power; if one variant is highly significant in one large study, the final meta-analysis result will likely still be significant, regardless of the results of other studies. However, meta-analyses are not designed for finding genetic variants for a condition without a comorbid condition, such as attention deficit hyperactivity disorder (ADHD) without autism spectrum disorder (ASD).

This study first utilized CombGWAS[5] to identify susceptibility variants underlying 16 psychiatric disorder combinations, encompassing disorders such as schizophrenia (SCZ), major depressive disorder (MDD), anxiety disorder and so on. Distinct from traditional methods such as LDSR and PRS analyses, our novel method of CombGWAS has the advantage of clarifying the genetic signature and *individual* genetic variants/genes contributing to the comorbidity, and thus may have better translational potential for precision medicine in psychiatry. Moreover, the proposed comprehensive statistical framework can address the challenge of arbitrary significance thresholds, enhancing the reliability and accuracy of the genetic evidence in this area. To enhance translational potential, our analytical framework also employed additional methods, including MAGMA, tissue specificity analysis, pathway enrichment analysis, genetic correlation analysis, Mendelian randomization (MR), which leverage the derived summary statistics to help us better understand the subtype-specific genetic signatures.

Method

Overview of the CombGWAS approach

In this study, we employed CombGWAS to estimate the genetic architecture of the combinations of psychiatric disorders. CombGWAS is a statistical framework specially designed to mimic the case-control GWAS by using summary statistics of the corresponding diseases only. The methodology is described below, with details given in our previous paper [5]. Consider $S \sim bin(n = 2, q)$ as a random biallelic SNP with q denoting the effect allele frequency. We considered two binary psychiatric-related traits P_1 and P_2, and generated a multivariate linear model on N subjects as follows:

$$\begin{bmatrix} P_{11} & P_{21} \\ P_{12} & P_{22} \\ \vdots & \vdots \\ P_{1N} & P_{2N} \end{bmatrix} = \begin{bmatrix} 1 & S_1 \\ 1 & S_2 \\ \vdots & \vdots \\ 1 & S_N \end{bmatrix} \begin{bmatrix} \beta_{01} & \beta_{02} \\ \beta_{11} & \beta_{12} \end{bmatrix} + \epsilon \qquad 1$$

The left-hand side is a $N \times 2$ phenotype matrix, the matrices on the right-hand side are separately $N \times 2$ SNP matrix, 2×2 association estimates matrix, and $N \times 2$ error matrix. Notably, the error matrix ($\epsilon \sim N(0, \sum)$) is assumed to follow a multivariate normal distribution.

The psychiatric condition which combined two disorders can be defined as a function of these two traits:

$$Comor = f(P_1, P_2) = P_1 \times P_2 \qquad 2$$

Similarly, the single psychiatric disorder (having the particular comorbid disorder excluded) can be defined as follows:

$$Single = f(P_1, P_2) = P_1 \times (1 - P_2) \qquad 3$$

Our goal here is to infer the association estimates for different SNPs for the target traits (i.e., the combined psychiatric disorders or the single psychiatric disorder without the particular comorbid disorder)

$$f(P_1, P_2) = : T = \gamma_0 + \gamma_1 S + e \qquad 4$$

Here, e is assumed to follow a normal distribution with zero mean. According to Yin et al.[5], the association estimates for the combined psychiatric disorders can be estimated as follows:

$$Comor(\widehat{\gamma_0}) = \widehat{\beta_{01}} \times \widehat{\beta_{02}} + Cov(P_1, P_2) \qquad 5$$

$$Comor(\widehat{\gamma_1}) = \frac{2q(1-q)}{2q(1-q)+q^2}\left[\left(\left(\widehat{\beta_{01}} + \widehat{\beta_{11}}\right) \times \left(\widehat{\beta_{02}} + \widehat{\beta_{12}}\right) - \widehat{\beta_{01}} \times \widehat{\beta_{02}}\right)\right] \qquad 6$$
$$+ \frac{q^2}{2q(1-q)+q^2} \frac{\left[\left(\left(\widehat{\beta_{01}} + 2\widehat{\beta_{11}}\right) \times \left(\widehat{\beta_{02}} + 2\widehat{\beta_{12}}\right) - \widehat{\beta_{01}} \times \widehat{\beta_{02}}\right)\right]}{2}$$

Here, $Cov(P_1, P_2)$ denotes the covariance between the two binary traits. Along the same line, the association estimates for the single psychiatric disorder without the particular comorbid disorder can be computed as follows:

$$Single(\widehat{\gamma_0}) = \widehat{\beta_{01}} \times (1 - \widehat{\beta_{02}}) - Cov(P_1, P_2) \quad 7$$

$$Single(\widehat{\gamma_1}) = \frac{2q(1-q)}{2q(1-q)+q^2}\left[\left(\left(\widehat{\beta_{01}} + \widehat{\beta_{11}}\right) \times \left(1 - \widehat{\beta_{02}} - \widehat{\beta_{12}}\right) - \widehat{\beta_{01}} \times (1 - \widehat{\beta_{02}})\right)\right] + \frac{q^2}{2q(1-q)+q^2}\frac{\left[\left(\left(\widehat{\beta_{01}} + 2\widehat{\beta_{11}}\right) \times \left(1 - \widehat{\beta_{02}} - 2\widehat{\beta_{12}}\right) - \widehat{\beta_{01}} \times (1 - \widehat{\beta_{02}})\right)\right]}{2} \quad 8$$

It is noteworthy that the estimates used in the above equations are presumably derived from a linear regression model. However, for binary traits, the associate estimates are usually calculated from logistic regression models. Therefore, we need to transform the estimates (odds ratios) derived from logistic regression to that of linear regression, using the following equation:

$$(\alpha k - k)(1-k) = \beta_1^2[p(1-p) + \alpha p(1-p)] + \beta_1[\alpha k(1-p) + \alpha p - \alpha pk + kp + (1-p)(1-k)] \quad 9$$

where p indicates the effect allele frequency of the SNP S under study, k represents the proportion of cases and β_1 represents the coefficient under a linear model, α defines the odds ratio of SNP S regressed on the same binary trait. The variance for $\widehat{\gamma_0}$ and $\widehat{\gamma_1}$ for the target disease combination can be estimated by the delta method. In brief, the delta method employs first-order Taylor expansion to estimate the variance of a function. The framework assumes the absence of interactions between the comorbid trait(s) and the genetic variants under study[5]. In our previous study [5], we have verified the validity of CombGWAS both using extensive simulations and applications to the UK-Biobank data. Briefly, we re-performed a GWAS in UKBB using the actual phenotype data of disease combinations as outcome; we found that the results were highly similar to those computed from CombGWAS.

Enrichment analyses

We utilized several methods to clarify the putative functional and biological mechanisms of the identified susceptibility genetic variants for the "psychiatric phenotypes/subtypes" of interest (i.e., the combined psychiatric disorders, and the single psychiatric disorder without the particular comorbid disorder). First, the MAGMA tool within FUMA [9,10] was used to map the identified genetic variants to their corresponding genes. This established the gene-level associations with the psychiatric phenotypes/subtypes. Second, we performed tissue specificity analysis to examine if the susceptibility genes were enriched in specific tissues. This "tissue specificity" analysis aimed to shed light on the potential involvement of particular tissues in the pathogenesis of the target psychiatric disorder. Furthermore, we carried out a "cell type" enrichment analysis to uncover specific cell types or cell populations that may play crucial roles in the etiology of the phenotypes/subtypes. To unravel unique biological pathways associated with specific psychiatric "comorbidity" to a specific primary disorder and those shared among different psychiatric phenotypes/subtypes, we conducted pathway analysis

using the program "ConsensusPathDB"[11,12]. Moreover, we performed drug enrichment analyses on the identified susceptibility gene sets using "enrichr" [13,14]. This analysis identified potential therapeutic agents or drug targets that may be relevant to the treatment of the investigated psychiatric conditions.

Genetic correlation among psychiatric disease subtypes and cardiovascular diseases

We employed LD score regression (LDSR) [6] to calculate the genetic correlation between different psychiatric entities to see if they represent genetically distinct disease subtypes with unique genetic architectures. Furthermore, we explored the genetic correlations between different psychiatric disorders of interest and several CVDs, including coronary artery disease (CAD), type 2 diabetes (T2DM), and stroke, highlighting possible links and comorbidities between these conditions.

Mendelian Randomization (MR) analysis

Mendelian Randomization (MR) is a method which leverages genetic variants as 'instruments' to represent the exposure, for inferring the causal relationship between risk factors and outcomes. Our MR estimated the causal effects of the studied psychiatric entities on various cardiovascular diseases. A two-sample MR design was employed, using MR estimates including inverse-variance weighted' (MR-IVW) [15] and Egger regression (MR-Egger) [16] approaches. The Egger intercept was also evaluated for evidence of imbalanced horizontal pleiotropy. We employed a p-value threshold of $p<5e-8$ and r2 threshold of 0.001. We also tried more relaxed p-value thresholds (p=1e-5, 1e-6, 1e-7) as secondary analyses but the findings were similar. Our analysis focused on assessing the causal effects of the studied psychiatric disorder entities on various cardiovascular diseases.

Psychiatric disorders studied

We applied the CombGWAS to examine 8 different psychiatric (related) disorders, i.e., Alzheimer's disease (AD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), anxiety disorders, insomnia, major depressive disorder (MDD), obesity, and schizophrenia (SCZ). The datasets used are shown in Supplementary Table S1. The lifetime risks for these disorders were directly extracted from the relevant literature. Using CombGWAS, we estimated the effect sizes (odds ratios (ORs)), standard errors (SEs) and corresponding p-values for each disease combination.

We successfully uncovered the genetic basis for 16 psychiatric entities, i.e., ADHD with and without comorbid ASD, MDD with and without AD, MDD with and without Anxiety Disorders, MDD with and without ASD, MDD with and without Insomnia, MDD with and without Obesity, MDD with and without SCZ, SCZ with and without Obesity. These 16 psychiatric entities were chosen, because of their relatively high prevalence rates (in particular MDD), and clinical relevance. Obesity was also considered in view of common comorbidities between psychiatric and cardiovascular disorders. Then we unveiled the unique genetic architecture and shared biological pathways contributing to their co-

occurrence. Our findings provide valuable insights into the complex interactions between these disorders, enabling the development of more accurate diagnostic tools, tailored treatment strategies, and improved patient outcomes. The definitions for independent significant SNPs and genomic risk loci in our study were based on the criteria established by FUMA, which can be found at the following URL: (https://fuma.ctglab.nl/tutorial#riskloci).



Figure 1. Manhattan plots of GWAS results for 16 psychiatric entities

Results

Results of enrichment analysis

Table 1 demonstrates the independent significant SNPs (p-value<5e-08, r^2<0.6) and genomic risk loci for the 8 comorbid psychiatric disorders and 8 single psychiatric entities (each having a single psychiatric disorder without the particular comorbid disorder). Our analysis revealed a total of 954 independent significant SNPs, mapped to 325 genomic risk loci, for the 8 comorbid psychiatric disorders (refer to Figure 1, Table 1 and Table S2). In addition, we identified 934 independent significant SNPs mapped to 328 genomic risk loci for the 8 single psychiatric entities (see Figure 1, Table 1 and Supplementary Table S2). These findings underscored the intricate genetic landscape underlying these psychiatric conditions and provide valuable insights into the susceptibility loci associated with their occurrence.

The identified susceptibility genetic variants were mapped to genes by MAGMA (see Supplementary Table S3). It showed a more comprehensive view of genetic signature underlying different combinations of psychiatric disorders. Our analysis revealed a mixture of susceptibility genes shared across multiple psychiatric entities, as well as condition-specific genes. For instance, MANBA and XRN2 were the top susceptibility genes identified in both the ADHD with ASD and ADHD without ASD. This finding is consistent with previous studies. Peyre et al [17] reported these two genes as susceptibility genes shared by ADHD and ASD. Conversely, SEMA6D was identified as a specific gene for ADHD without ASD. Dark et al. [18] have demonstrated that SEMA6D could inhibit axon extension and induce growth cone collapse in ADHD patients. Interestingly, defected axon extension and collapsed growth cone have also been implicated in the etiology of ASD patients, However, they were induced by different genetic factors, e.g., XRXN1, and SHANKS, as shown in a study by McFadden et al.[18]. Notably, SORCS3 was found to be associated with all 12 studied psychiatric entities involving MDD. Previous studies have highlighted its critical role in regulating neuronal viability and function [19-21]. Furthermore, Brediderhoff et al. [22] implicated that it could induce damage to fear memory modulation through altered synaptic plasticity. Supplementary Table S3 provides additional details of the shared and specific genes associated with psychiatric entities we studied.

Table 1. Number of identified independent significant SNPs and genomic risk loci for different combinations of psychiatric disorders

Disease subtypes	No. of ind. sig. SNPs	No. risk loci	Disease subtypes	No. of ind. sig. SNPs	No. risk loci
ADHD with ASD	20	19	ADHD without ASD	23	12
MDD with AD	148	37	MDD without AD	153	53
MDD with Anxiety	209	73	MDD without Anxiety	139	52
MDD with ASD	3	3	MDD without ASD	149	51
MDD with Insomnia	111	48	MDD without Insomnia	111	39
MDD with Obesity	50	21	MDD without Obesity	44	21
MDD with SCZ	330	95	MDD without SCZ	146	52
SCZ with Obesity	83	29	SCZ without Obesity	169	48

Note: No., number. No. of ind. sig. SNPs, number of individual significant SNPs.

In addition, we performed tissue enrichment analysis using FUMA. This analysis involved pre-computed list of differentially expressed genes (DEGs) in various tissues (DEGs) obtained from GTEx; input genes (significant genes from MAGMA analysis in GWAS) were then tested for enrichment for these DEGs. We consider this as a hypothesis-generating analysis as differential expression does not always suggest causal role of the tissue. Supplementary Figure S1 shows the tissue enrichment analysis results for all 16 studied psychiatric entities we studied. We observed that all the entities showed enrichment predominantly in brain tissues[23,24]. Interestingly, basal ganglia emerged as the top-enriched tissue for all psychiatric entities involving ADHD or ASD. Abundant evidence supports its critical role in maintaining normal motor actions and cognitive functions [25-27]. In a previous study by Curtin et al. [28], ADHD was associated with 2.4-fold increased risk of basal ganglia diseases. Another intriguing finding is that the cerebellum was the top-enriched tissue for all disease combinations involved MDD. A growing body of research has demonstrated its involvement in impaired cognitive function and emotion dysregulation [29-31]. Compared to other psychiatric entities involving MDD, the two conditions involving obesity (i.e., MDD with obesity and MDD without obesity) exhibited a lower number of enriched brain tissues, with cerebellar hemisphere ranked as the top-enriched tissue. Further investigation is required to establish causal relationships and unravel the mechanisms underlying each psychiatric entity.

We conducted pathway analysis using ConsensusPathDB (see Supplementary Table S4). We observed a mixture of shared and condition-specific enriched pathways across different psychiatric entities, while others were specific to a particular condition. For instance, Signaling by Nuclear Receptors was one of the top-enriched pathways shared between MDD with AD and MDD without AD. In a previous study, Fries et al.[32] have highlighted the critical role of this pathway in coordinating organism's response to stress, which is a well-established risk factor for MDD. Additionally, Mandrekar-Colucci et al.[33] recommended nuclear receptors as a promising therapeutic target for AD, as they could regulate microglial activation and suppress the inflammatory milieu of the brain. In contrast, the cardiolipin biosynthesis pathway was specifically enriched in MDD with AD. Falabella et al.[34] have implicated the associations between brain cardiolipin alternations and impaired neuronal function and neurodegeneration, contributing to the pathogenesis of neurodegenerative diseases. Notably, we did not find any common pathways between ADHD with and without ASD, as well as between MDD with and without ASD. Our investigation of enriched pathways enriched aimed to uncover both the biological mechanisms that are generally important across psychiatric disorders and more 'specific' mechanisms that may play a more salient role for certain disease combinations. The findings suggest the possibility of distinct biological subtypes within these diseases. However, further investigations are required before any definitive conclusions are made.

Cell type enrichment analyses were also performed to uncover the involved cell types for each studied disease combinations (see Figure 2). However, not all cell types were available for analysis in FUMA, thus our results were considered exploratory. We found that GABAergic neurons were the most enriched cell types in most psychiatric entities/comorbidities. Fogoca et al.[35] have reported that decreased expression of GABAergic interneuron markers in the frontal cortex could result in depressive-like behaviors. Furthermore, defected GABAergic neurotransmission has been implicated in depression, and therapeutic strategies targeted this deficit have been developed [36]. It is noteworthy that the top-enriched cell types for the studied psychiatric disease combinations were all located in brain tissues.



Figure 2 Cell type enrichment analysis results for each studied psychiatric disease combination

To further explore the homogeneity and heterogeneity underlying the studied psychiatric entities, we performed drug enrichment analysis on the susceptibility gene set identified for each disease combination (see Supplementary Table S5). As anticipated, some enriched drugs were unique to particular psychiatric entities, while others were concordant among different psychiatric entities. For example, chlorprothixene was one of the top-enriched drugs specific to ADHD and ASD. It is a typical antipsychotic that may be used for patients with ADHD and ASD[37]. Among all disease combinations involved MDD, except for MDD with ASD, azacyclonol and fendiline were the top-enriched drugs. Azacyclonol, a commonly used drug in 1950s and 1960s for the treatment of psychotic disorders, has been known to diminish hallucination in patients [38]. Previous study by So et al. [39] have suggested

fendiline as a promising repurposing drug for MDD patients. For more detailed findings of drug enrichment analysis, please refer to Supplementary Table S5.

Genetic correlation among psychiatric disease subtypes and cardiovascular diseases

We calculated the genetic correlations between pairs of psychiatric entities with and without the particular comorbid condition (see Table 2). The results revealed moderate to high genetic correlations in many pairs, suggesting shared genetic architecture. For instance, MDD with Anxiety Disorder exhibited a high genetic correlation with MDD without Anxiety Disorder (rg = 0.9964). Similarly, a high genetic correlation was also observed between SCZ with and without Obesity (rg = 0.9016). Interestingly, MDD with Obesity only displayed a weak genetic correlation with MDD without Obesity, implying they may represent *distinct biological subtypes* of the disease (rg = 0.1663).

To further investigate the genetic overlap between psychiatric entities and cardiovascular diseases, we analyzed their genetic correlations by LDSR (refer to Table 3 and Table S6). As shown in Table 3, most pairs of psychiatric entities exhibited significantly different genetic correlations with various cardiovascular diseases, indicating distinct genetic relationships. Interestingly, some psychiatric "subtypes" displayed reverse genetic correlations with the same cardiovascular disease. For example, while SCZ with Obesity exhibited a positive genetic correlation with type 2 diabetes (T2DM) (rg=0.2481), whereas SCZ without Obesity demonstrated a negative genetic correlation with T2DM (rg=-0.1539). Similarly, SCZ with Obesity and SCZ without Obesity showed opposite genetic correlation with coronary artery disease (CAD). Notably, the genetic correlations between "un-subtyped"(originally defined) psychiatric disorders and cardiovascular diseases generally lie between that for "subtyped"(comorbid or only single) disorders. These findings highlight the complex genetic architecture associated with psychiatric entities and cardiovascular diseases, indicating potential distinct genetic signatures and biological links to CVD for different psychiatric entities.

Table 2. Genetic correlation between different psychiatric entities

1st trait	2nd trait	rg	P
MDD with Insomnia	MDD without Insomnia	0.7915 (0.0117)	0
MDD with SCZ	MDD without SCZ	0.5713 (0.0172)	9.05E-243
MDD with Obesity	MDD without Obesity	0.1663 (0.0309)	7.18E-08
MDD with ASD	MDD without ASD	0.6830 (0.0214)	6.50E-224
ADHD with ASD	ADHD without ASD	0.8167 (0.0163)	0
MDD with Anxiety	MDD without Anxiety	0.9964 (0.001)	0
MDD with AD	MDD without AD	1.0255 (0.0265)	0
SCZ with Obesity	SCZ without Obesity	0.9016 (0.0133)	0

Here, rg indicates the calculated genetic correlation between two disease "subtypes".

Table 3 Genetic correlation between psychiatric entities and cardiovascular diseases

1st trait	2nd trait	rg	P

SCZ with Obesity	CAD	0.1014 (0.0247)	3.89E-05
SCZ	CAD	-0.0239 (0.0229)	2.98E-01
SCZ without Obesity	CAD	-0.0709 (0.0243)	3.50E-03
SCZ with Obesity	Stroke	0.1189 (0.0369)	1.2E-03
SCZ	Stroke	0.0476 (0.0332)	1.52E-01
SCZ without Obesity	Stroke	0.0549 (0.0382)	1.50E-01
SCZ with Obesity	T2DM	0.2481 (0.0226)	4.42E-28
SCZ	T2DM	-0.0471 (0.0177)	7.7E-03
SCZ without Obesity	T2DM	-0.1539 (0.0382)	6.79E-12
MDD with Obesity	CAD	0.2795 (0.0302)	2.40E-20
MDD	CAD	0.1988 (0.025)	1.92E-15
MDD without Obesity	CAD	0.0323 (0.0253)	2.02E-01
MDD with Obesity	Stroke	0.1651 (0.0396)	3.03E-05
MDD	Stroke	0.0717 (0.0416)	8.46E-02
MDD without Obesity	Stroke	-0.0279 (0.0419)	5.05E-01
MDD with Obesity	T2DM	0.5041 (0.0273)	4.48E-76
MDD	T2DM	0.1395 (0.0212)	4.72E-11
MDD without Obesity	T2DM	-0.1895 (0.0273)	3.47E-12
MDD without Insomnia	CAD	0.1868 (0.0271)	5.49E-12
MDD	CAD	0.1988 (0.025)	1.92E-15
MDD with Insomnia	CAD	0.2564 (0.0275)	1.134E-20
MDD without SCZ	CAD	0.2009 (0.0247)	4.57E-16
MDD	CAD	0.1988 (0.025)	1.92E-15
MDD with SCZ	CAD	0.0432 (0.0228)	5.84E-02
MDD without ASD	CAD	0.2065 (0.0269)	1.49E-14
MDD	CAD	0.1988 (0.025)	1.92E-15
MDD with ASD	CAD	0.0369 (0.0326)	2.57E-01
MDD without ASD	Stroke	0.0766 (0.0429)	7.43E-02
MDD	Stroke	0.0717 (0.0416)	8.46E-02
MDD with ASD	Stroke	-0.0587 (0.0515)	2.54E-01
ADHD without ASD	CAD	0.2815 (0.0344)	2.67E-16
ADHD	CAD	0.2793 (0.0342)	2.99E-16
ADHD with ASD	CAD	0.1508 (0.0355)	2.19E-05
ADHD without ASD	Stroke	0.2131 (0.0543)	8.72E-05
ADHD	Stroke	0.2098 (0.0543)	1.00E-04
ADHD with ASD	Stroke	0.0752 (0.0594)	2.06E-01
ADHD without ASD	DM	0.3220 (0.0277)	2.90E-31
ADHD	DM	0.3205 (0.0275)	1.86E-31
ADHD with ASD	DM	0.2326 (0.0281)	1.11E-16
MDD without Anxiety	CAD	0.1998 (0.0253)	2.89E-15
MDD	CAD	0.1988 (0.025)	1.92E-15
MDD with Anxiety	CAD	0.1942 (0.0254)	2.10E-14
MDD without Anxiety	Stroke	0.7270 (0.0419)	8.25E-02
MDD	Stroke	0.0717 (0.0416)	8.46E-02
MDD with Anxiety	Stroke	0.0673(0.0417)	1.07E-01
MDD without Anxiety	DM	0.1408 (0.0212)	3.34E-11
MDD	DM	0.1395 (0.0212)	4.72E-11
MDD with Anxiety	DM	0.1299(0.0215)	1.44E-09
MDD without AD	CAD	0.1996 (0.0255)	5.17E-15
MDD	CAD	0.1988 (0.025)	1.92E-15
MDD with AD	CAD	0.1987(0.0272)	2.64E-13
MDD without AD	Stroke	0.0689 (0.0417)	9.81E-02
MDD	Stroke	0.0717 (0.0416)	8.46E-02
MDD with AD	Stroke	0.0909(0.0438)	3.81E-02
MDD without AD	DM	0.1359 (0.0213)	1.63E-10
MDD	DM	0.0717 (0.0416)	8.46E-02
MDD with AD	DM	0.1699(0.0258)	4.61E-11

Here, rg indicates the calculated genetic correlation between two psychiatric disorder subtypes and cardiovascular diseases. CAD, coronary artery disease, DM, diabetes mellitus.

Results of MR analysis

MR analysis was conducted to investigate whether a certain psychiatric disease combination confer significant risk to a particular cardiovascular outcome. Notably, most results were consistent across different r^2 cutoffs. For simplicity, we only report analysis results at $r^2 = 0.001, p = 5E - 08$.

Table 4 summarizes the analysis results (please refer to Supplementary Table S7 for full results). Many studied psychiatric disease combinations exhibited a significant causal relationship with increased risks of cardiovascular disease. Importantly, the magnitude of effect sizes varies across different risk factors. For example, both MDD with and without Anxiety were found be causally linked to significantly increased CAD risk, the OR of MDD with Anxiety on CAD is 2.106(MR-IVW, p=2.35E-05), while that of MDD without Anxiety on CAD is 1.108(MR-Egger, p=3.78E-05).

Additionally, we found that comorbid psychiatric disorders represented more profound risk factors for cardiovascular outcome than only single disorders. For example, MDD with Insomnia was found to be causally related to a significantly increased risk of CAD with an OR of 3.721(MR-IVW, p=1.72E-06) while MDD without Insomnia had a much lower OR of 1.054(MR-IVW, p=2.71E-03).

Both obese MDD and obese SCZ were found to be causally related to increased T2DM risk. More specifically, obese MDD and obese SCZ respectively showed significant causal links to T2DM risk with an OR of 5.418(MR-IVW, p=3.58E-06) and 1.364(MR-Egger, p=2.81E-03). In contrast, non-obese MDD(MR-Egger, OR=0.292, p=9.87E-04) and non-obese SCZ(MR-Egger, OR=0.948, p=2.58E-02) were associated with significantly decreased T2DM risk. Previous study has confirmed the importance of maintaining a normal body weight in the prevention of type 2 diabetes, even among individuals with low genetic risk and a favorable lifestyle [40].

These findings highlight the causal relationships between specific psychiatric disease combinations and various cardiovascular outcomes. However, it is essential to conduct further research to elucidate the underlying mechanisms and potential implications for disease management and prevention strategies.

Table 4. MR analysis results for cardiovascular outcomes

Exposure	Outcome	OR(2.72 times of exposure preval)	P	Exposure	Outcome	OR(2.72 times of exposure preval)	P
ADHD with ASD	CAD	1.350	2.04E-01	ADHD without ASD	CAD	1.047	2.71E-01
ADHD with ASD	DM	0.312	**8.05E-02***	ADHD without ASD	DM	1.102	**1.58E-05**
ADHD with ASD	Stroke	1.680	**4.84E-02**	ADHD without ASD	Stroke	1.083	**4.76E-02**
MDD with AD	CAD	1.310	**1.97E-10**	MDD without AD	CAD	0.594	1.1.3E-01*
MDD with AD	DM	0.712	**2.14E-05***	MDD without AD	DM	1.224	**4.23E-03**
MDD with AD	Stroke	1.059	3.87E-01	MDD without AD	Stroke	1.037	5.36E-01
MDD with Anxiety	CAD	2.106	**2.35E-05**	MDD without Anxiety	CAD	1.108	**3.78E-05**
MDD with Anxiety	DM	1.917	**3.03E-03**	MDD without Anxiety	DM	1.109	**3.76E-04**
MDD with Anxiety	Stroke	1.537	***5.79E-02***	MDD without Anxiety	Stroke	1.045	1.56E-01
MDD with ASD	CAD	1.088	1.69E-01	MDD without ASD	CAD	1.184	**3.60E-05**
MDD with ASD	DM	1.007	9.82E-01	MDD without ASD	DM	1.166	**1.99E-03**
MDD with ASD	Stroke	1.062	5.90E-01	MDD without ASD	Stroke	1.058	2.70E-01
MDD with Insomnia	CAD	3.721	**1.72E-06**	MDD without Insomnia	CAD	1.054	**2.71E-03**

MDD with Insomnia	DM	2.115	**1.59E-02**	MDD without Insomnia	DM	1.056	**7.31E-03**
MDD with Insomnia	Stroke	1.340	2.67E-01	MDD without Insomnia	Stroke	1.027	2.46E-01
MDD with Obesity	CAD	1.365	**1.81E-07**	MDD without Obesity	CAD	0.919	1.94E-01
MDD with Obesity	DM	5.418	**3.58E-06***	MDD without Obesity	DM	0.292	**9.87E-04***
MDD with Obesity	Stroke	1.078	2.09E-01	MDD without Obesity	Stroke	0.943	***8.52E-02***
MDD with SCZ	CAD	1.059	2.28E-01	MDD without SCZ	CAD	1.211	**4.64E-05**
MDD with SCZ	DM	0.964	3.63E-01	MDD without SCZ	DM	1.182	**3.52E-03**
MDD with SCZ	Stroke	1.031	4.92E-01	MDD without SCZ	Stroke	1.061	3.28E-01
SCZ with Obesity	CAD	1.117	**1.83E-02**	SCZ without Obesity	CAD	1.156	**2.91E-02***
SCZ with Obesity	DM	1.364	**2.81E-03**	SCZ without Obesity	DM	0.948	**2.58E-02**
SCZ with Obesity	Stroke	1.106	***6.94E-02***	SCZ without Obesity	Stroke	1.009	5.43E-01

Note: The above MR results were mainly based on MR-IVW, if the Egger intercept is non-significant. * indicates that the causal analysis results were derived from MR-Egger instead of MR-IVW due to the presence of imbalanced pleiotropy, as indicated by a significant Egger intercept. The effect estimate from MR reflects the odds ratio per 2.72 times the prevalence (preval) of the exposure [41].

Discussion

This study applied the CombGWAS statistical framework to uncover the genetic basis underlying different combinations of psychiatric disorders. Specifically, we studied the genetic architecture of 16 distinct psychiatric entities, consisting of 8 pairs of subtypes representing comorbid and only single psychiatric disorders respectively. Through this analysis, we successfully identified a total of 653 susceptibility genomic risk loci associated with these psychiatric disorder entities. Among these loci, 325 were found to be specifically associated with comorbid disorders, while 328 were associated with single psychiatric disorders (without a relevant comorbidity).

In addition to the primary analysis, we conducted a series of secondary analyses to delve deeper into the shared and distinct genetic signatures underlying the 8 pairs of distinct psychiatric disease subtypes. These analyses aimed to elucidate the genetic factors contributing to the development and manifestation of these specific subtypes. By examining the genetic overlap and unique genetic variations within each pair, we gained further insights into the genetic complexity and heterogeneity of psychiatric disorders. These findings contribute to a more comprehensive understanding of the genetic landscape and potential mechanisms underlying the co-occurrence of psychiatric disorders and provide valuable information for future research and therapeutic interventions.

To our knowledge, this is the first work to comprehensively study the genetic basis (at the SNP-, gene- and pathway-levels) of a wide variety of psychiatric comorbidities (and

psychiatric disorder without a relevant comorbidity). This may also be the first study to report genetic correlations and potential causal effects of psychiatric comorbidities with various CVD.

Shared and unique genetic underpinnings

Shared genetic basis was identified across all 8 pairs of subtypes, suggesting an overlap of genetic risks across different combinations of psychiatric disorders. Notably, degree of genetic correlation varies across different subtype pairs. Specifically, we observed substantial genetic correlation between MDD with Anxiety Disorder and MDD without Anxiety Disorder. Conversely, a relatively modest genetic correlation was found between MDD with Obesity and MDD without Obesity, suggesting they may be distinct biological subtypes. Notably, we also identified the specific genetic variants associated with different comorbidities, which shed light on the pathophysiology of these psychiatric entities. We believe our findings may be useful in the development of effective treatment and preventive strategies for specific psychiatric disease combinations in the long term.

Furthermore, our analysis of enriched pathways, cell types, and drugs revealed interesting patterns. These enrichment analyses provide us a deeper understanding of the shared and unique genetic basis underlying different psychiatric disease subtypes, and shed light on the potential biological mechanisms and pathways involved in the development and manifestation of specific subtypes.

Genetic correlations among disease subtypes and cardiovascular diseases

The majority of disease subtypes exhibited high ($rg>=0.8$) or moderate ($0.4<rg<0.8$) correlation with one another. Among the 8 pairs of subtypes examined, only one pair, i.e., MDD with Obesity vs MDD without Obesity, demonstrated weak correlation. Despite their high genetic correlation, most subtype pairs exhibited distinct genetic correlations with the same cardiovascular disease. In fact, some pairs displayed entirely opposing genetic correlation, particularly those subtype pairs involved obesity. These findings suggest that the studied combinations of psychiatric disorders may probably be associated with different levels cardiovascular risks.

Accumulating evidence suggests that normal weight may exert a protective effect against cardiovascular diseases[42]. In this context, it is hypothesized that normal weight may counteract the increased cardiovascular disease risk induced by psychiatric disorders. The

observed opposing/weak genetic correlations between SCZ without obesity, as well as MDD without obesity and three cardiovascular diseases align with this hypothesis.

Distinctive causal effects on various cardiovascular outcomes

Many studied combinations of psychiatric disorders were associated with increased cardiovascular disease risks. However, comorbid psychiatric disorders typically exhibited distinct causal relations from only single psychiatric disorders on same cardiovascular diseases. The observed differences in MR causal effects between comorbid and single psychiatric disorders highlight the importance of considering the cumulative impact of multiple disorders on cardiovascular health. Of note, obese and non-obese psychiatric disorders showed opposite causal effect on T2DM risk. These findings underscore the need for comprehensive screening, prevention, and treatment strategies that address both psychiatric and cardiovascular conditions in individuals with comorbidities. Based on our findings, it is possible that individuals with different psychiatric comorbidities may warrant different metabolic screening and CVD prevention strategies. Further research is warranted to elucidate the specific mechanisms underlying these distinctive causal effects and to identify potential targets for intervention and risk reduction in this vulnerable population.

Limitations

This study has several limitations. Firstly, the summary statistics used for the estimation of genetic basis of combinations of psychiatric disorders were primarily derived from European samples. As such, some results may be population specific and may not be generalizable to non-European groups. This limitation could be mitigated with the availability of summary statistics from other ethnic groups. While our analysis provides valuable insights into the share and unique genetic signatures underlying different psychiatric disease subtypes, further exploration is required to validate these findings. Replication studies using independent cohorts and diverse populations would enhance the robustness and generalizability of the observed genetic associations. Besides, our study only included a limited number of psychiatric disease combinations. Future work may involve extending the analysis to more psychiatric traits and disorders.

To conclude, our study successfully identified the genetic basis and susceptibility genes for the 8 pairs of psychiatric disease subtypes. Secondary analyses, including gene, pathway, cell type enrichment analysis, further implicated the shared and unique genetic signatures

between different ‘subtypes’. Genetic correlation and MR analyses further corroborated their biological distinctiveness. The identified susceptibility genes may help us differentiate different ‘subtypes’. In addition, we observed genetic correlation and/or causal effect estimates with various CVD, which suggests our findings may be clinically relevant. Future research should incorporate data from diverse ethnic groups, conduct replication studies, and employ functional investigations to enhance the robustness and generalizability of the observed genetic associations. By elucidating the genetic basis of 8 pairs psychiatric disorder subtypes, our study paves the way for the development of personalized treatment and preventive strategies for individuals affected by these complex disorders.

Conflicts of interest

The authors declare no relevant conflicts of interest.

Acknowledgements

This work was supported partially by a National Natural Science Foundation China (NSFC) Young Scientist Grant (31900495), a National Natural Science Foundation China grant (81971706), the Lo Kwee Seong Biomedical Research Fund from The Chinese University of Hong Kong and the KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, Kunming Institute of Zoology and The Chinese University of Hong Kong, China.

References

1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the global burden of disease study 2019. *The Lancet*. 2020;396(10258):1204-1222.

2. Gorman JM. Comorbid depression and anxiety spectrum disorders. *Depress Anxiety*. 1996;4(4):160-168.

3. Pantelis C, Papadimitriou GN, Papiol S, et al. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427.

4. Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. *Nature Reviews Methods Primers*. 2021;1(1):59.

5. Yin L, Chau CK, Lin Y, et al. A framework to decipher the genetic architecture of combinations of complex diseases: Applications in cardiovascular medicine. *Bioinformatics*. 2021;37(22):4137-4147.

6. Bulik-Sullivan BK, Loh P, Finucane HK, et al. LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47(3):291-295.

7. Choi SW, Mak TS, O'Reilly PF. Tutorial: A guide to performing polygenic risk score analyses. *Nature protocols*. 2020;15(9):2759-2772.

8. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies and beyond. *Nature Reviews Genetics*. 2013;14(6):379-389.

9. Watanabe K, Taskesen E, Van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nature communications*. 2017;8(1):1826.

10. Watanabe K, Umićević Mirkov M, de Leeuw CA, van den Heuvel MP, Posthuma D. Genetic mapping of cell type specificity for complex traits. *Nature communications*. 2019;10(1):3222.

11. Herwig R, Hardt C, Lienhard M, Kamburov A. Analyzing and interpreting genome data at the network level with ConsensusPathDB. *Nature protocols*. 2016;11(10):1889-1907.

12. Kamburov A, Stelzl U, Lehrach H, Herwig R. The ConsensusPathDB interaction database: 2013 update. *Nucleic Acids Res*. 2013;41(D1):D793-D800.

13. Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res*. 2016;44(W1):W90-W97.

14. Xie Z, Bailey A, Kuleshov MV, et al. Gene set knowledge discovery with enrichr. *Current protocols*. 2021;1(3):e90.

15. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol*. 2016;40(4):304-314.

16. Burgess S, Thompson SG. Interpreting findings from mendelian randomization using the MR-egger method. *Eur J Epidemiol*. 2017;32:377-389.

17. Peyre H, Schoeler T, Liu C, et al. Combining multivariate genomic approaches to elucidate the comorbidity between autism spectrum disorder and attention deficit hyperactivity disorder. *Journal of Child Psychology and Psychiatry*. 2021;62(11):1285-1296.

18. Dark C, Homman-Ludiye J, Bryson-Richardson RJ. The role of ADHD associated genes in neurodevelopment. *Dev Biol*. 2018;438(2):69-83.

19. Willnow TE, Petersen CM, Nykjaer A. VPS10P-domain receptors—regulators of neuronal viability and function. *Nature Reviews Neuroscience*. 2008;9(12):899-909.

20. Jansen P, Giehl K, Nyengaard JR, et al. Roles for the pro-neurotrophin receptor sortilin in neuronal development, aging and brain injury. *Nat Neurosci*. 2007;10(11):1449-1457.

21. Vaegter CB, Jansen P, Fjorback AW, et al. Sortilin associates with trk receptors to enhance anterograde transport and neurotrophin signaling. *Nat Neurosci*. 2011;14(1):54-61.

22. Breiderhoff T, Christiansen GB, Pallesen LT, et al. Sortilin-related receptor SORCS3 is a postsynaptic modulator of synaptic depression and fear extinction. *PloS one*. 2013;8(9):e75006.

23. Maddock RJ, Buonocore MH. MR spectroscopic studies of the brain in psychiatric disorders. *Brain imaging in behavioral neuroscience*. 2012:199-251.

24. Karlsgodt KH, Sun D, Cannon TD. Structural and functional brain abnormalities in schizophrenia. *Current directions in psychological science*. 2010;19(4):226-231.

25. Graybiel AM. Habits, rituals, and the evaluative brain. *Annu.Rev.Neurosci.* 2008;31:359-387.

26. Damasio AR, Maurer RG. A neurological model for childhood autism. *Arch Neurol*. 1978;35(12):777-786.

27. Jin X, Costa RM. Shaping action sequences in basal ganglia circuits. *Curr Opin Neurobiol*. 2015;33:188-196.

28. Curtin K, Fleckenstein AE, Keeshin BR, et al. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. *Neuropsychopharmacology*. 2018;43(13):2548-2555.

29. Depping MS, Schmitgen MM, Kubera KM, Wolf RC. Cerebellar contributions to major depression. *Frontiers in psychiatry*. 2018;9:634.

30. Depping MS, Schmitgen MM, Bach C, et al. Abnormal cerebellar volume in patients with remitted major depression with persistent cognitive deficits. *The Cerebellum*. 2020;19:762-770.

31. Hoche F, Guell X, Vangel MG, Sherman JC, Schmahmann JD. The cerebellar cognitive affective/schmahmann syndrome scale. *Brain*. 2018;141(1):248-270.

32. Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder converge on the synapse. *Mol Psychiatry*. 2023;28(1):284-297.

33. Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for alzheimer's disease. *Expert opinion on therapeutic targets*. 2011;15(9):1085-1097.

34. Falabella M, Vernon HJ, Hanna MG, Claypool SM, Pitceathly RD. Cardiolipin, mitochondria, and neurological disease. *Trends in Endocrinology & Metabolism*. 2021;32(4):224-237.

35. Fogaça MV, Duman RS. Cortical GABAergic dysfunction in stress and depression: New insights for therapeutic interventions. *Frontiers in cellular neuroscience*. 2019:87.

36. Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. *Neuron*. 2019;102(1):75-90.

37. Strålin P, Hetta J. First episode psychosis and comorbid ADHD, autism and intellectual disability. *European Psychiatry*. 2019;55:18-22.

38. Brown BB, Braun DL, Feldman RG. THE PHARMACOLOGIC ACTIVITY OF α-(4-PIPERIDYL)-BENZHYDROL HYDROCHLORIDE (AZACYCLONOL HYDROCHLORIDE); AN ATARACTIVE AGENT. *J Pharmacol Exp Ther*. 1956;118(2):153-161.

39. So H, Chau CK, Lau A, Wong S, Zhao K. Translating GWAS findings into therapies for depression and anxiety disorders: Gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning. *Psychol Med*. 2019;49(16):2692-2708.

40. Schnurr TM, Jakupović H, Carrasquilla GD, et al. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: A case-cohort study. *Diabetologia*. 2020;63:1324-1332.

41. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable: Interpretation and presentation of causal estimates. *Eur J Epidemiol*. 2018;33:947-952.

42. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: A scientific statement from the american heart association. *Circulation*. 2011;123(20):2292-2333.